Healthier Capital

Healthier Capital

Amir Dan Rubin established Healthier Capital as a private investment firm drawing on his career operating at the intersection of healthcare delivery, technology, and consumer experience. Before founding the firm, Rubin served as CEO of One Medical, guiding the primary care network through its IPO and subsequent $3.9 billion acquisition by Amazon in 2022. He previously held president and executive roles at Optum, Stanford Health Care, and Stony Brook Medicine. The firm's operational DNA reflects that arc — an investor that brings health-system and payer-side fluency to growth-stage companies rather than managing passive pools of capital. The firm targets expansion-stage and late-stage venture opportunities where technology reshapes how care is accessed, paid for, and delivered. Sectors of focus include digital health platforms, care delivery innovation, and artificial intelligence applications within healthcare administration and clinical workflows. Healthier Capital distinguishes itself by concentrating on a small number of portfolio positions — a model shaped by Rubin's stated belief that meaningful transformation requires deep engagement rather than index-style diversification. The geographic footprint spans US-based health-tech hubs, consistent with the firm's multi-city office presence across San Francisco, New York, Nashville, Boston, and Salt Lake City. Team scale and fund size are undisclosed as of mid-2026. The firm operates without published sidecar vehicles or philanthropic foundations tied to its investment activities, though Rubin's prior institutional leadership at Amazon and UnitedHealth Group provides the networks typically associated with sourcing proprietary health-tech deal flow. The Salt Lake City and Nashville offices align with growing health-services and tech corridors where the firm may scout for operator-led companies outside the coastal venture concentration. A genuine structural differentiator lies in the founder's blended background: a former large-scale CEO who navigated a marquee exit to a public company acquirer now deploying his own capital model. That dual lens of operator and allocator creates a diligence posture that peers in the health-tech venture space rarely replicate — one that evaluates both clinical workflow ROI and sell-side exit velocity simultaneously.